Class IITerminatedD-0761-2023
Drug recall · May 31, 2023
buPROPrion Hydrochloride Extended-Release Tablets recall
Why: Failed Dissolution Specifications; during stability testing
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
buPROPrion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg, 60 Tablets, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ, Manufactured by: Sun Pharmaceutical Industries Limited, Gujrat, India, NDC 47335-737-86
- Lots / codes
Lots: HAC2240A, Exp 05/2023; HAC3162A, Exp 07/2023
- Quantity
- 5,344 Bottles
- Company
- Sun Pharmaceutical Industries Inc, Princeton, NJ
- Distribution
- Nationwide in the U.S.A
- Initiated
- May 9, 2023 · Voluntary: Firm initiated
- Classified
- May 23, 2023
- Reported
- May 31, 2023
- Ended
- February 27, 2024
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.